JP2017533888A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533888A5
JP2017533888A5 JP2017515768A JP2017515768A JP2017533888A5 JP 2017533888 A5 JP2017533888 A5 JP 2017533888A5 JP 2017515768 A JP2017515768 A JP 2017515768A JP 2017515768 A JP2017515768 A JP 2017515768A JP 2017533888 A5 JP2017533888 A5 JP 2017533888A5
Authority
JP
Japan
Prior art keywords
antigen
amino acid
seq
binding fragment
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017515768A
Other languages
English (en)
Japanese (ja)
Other versions
JP6694877B2 (ja
JP2017533888A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/051407 external-priority patent/WO2016049000A2/en
Publication of JP2017533888A publication Critical patent/JP2017533888A/ja
Publication of JP2017533888A5 publication Critical patent/JP2017533888A5/ja
Priority to JP2020002597A priority Critical patent/JP6916319B2/ja
Application granted granted Critical
Publication of JP6694877B2 publication Critical patent/JP6694877B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017515768A 2014-09-23 2015-09-22 抗il−25抗体およびその使用 Active JP6694877B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020002597A JP6916319B2 (ja) 2014-09-23 2020-01-10 抗il−25抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462054167P 2014-09-23 2014-09-23
US62/054,167 2014-09-23
PCT/US2015/051407 WO2016049000A2 (en) 2014-09-23 2015-09-22 Anti-il-25 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020002597A Division JP6916319B2 (ja) 2014-09-23 2020-01-10 抗il−25抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2017533888A JP2017533888A (ja) 2017-11-16
JP2017533888A5 true JP2017533888A5 (enExample) 2018-10-25
JP6694877B2 JP6694877B2 (ja) 2020-05-20

Family

ID=54207847

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017515768A Active JP6694877B2 (ja) 2014-09-23 2015-09-22 抗il−25抗体およびその使用
JP2020002597A Active JP6916319B2 (ja) 2014-09-23 2020-01-10 抗il−25抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020002597A Active JP6916319B2 (ja) 2014-09-23 2020-01-10 抗il−25抗体およびその使用

Country Status (18)

Country Link
US (3) US9840557B2 (enExample)
EP (1) EP3197914B1 (enExample)
JP (2) JP6694877B2 (enExample)
KR (1) KR102576368B1 (enExample)
CN (1) CN107207589B (enExample)
AU (1) AU2015321517B2 (enExample)
CA (1) CA2961517C (enExample)
CL (2) CL2017000703A1 (enExample)
CO (1) CO2017003072A2 (enExample)
EA (1) EA036658B1 (enExample)
IL (1) IL251001B (enExample)
MA (1) MA40106A1 (enExample)
MX (1) MX2017003841A (enExample)
MY (1) MY185832A (enExample)
PH (1) PH12017500403A1 (enExample)
SG (2) SG11201701712WA (enExample)
WO (1) WO2016049000A2 (enExample)
ZA (1) ZA201701663B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840557B2 (en) 2014-09-23 2017-12-12 Regeneron Pharmaceuticals, Inc. Anti-IL-25 antibodies and uses thereof
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗il−13抗体を使用する、il−13活性が有害である疾患の治療方法
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
CN107213463A (zh) * 2017-05-24 2017-09-29 清华大学 白介素25在银屑病的发育中的作用
DE102017215154A1 (de) 2017-08-30 2019-02-28 Markus Bläss Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen
KR102598319B1 (ko) * 2018-11-19 2023-11-02 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 항-il-25 항체 및 그의 용도
WO2021127500A1 (en) 2019-12-20 2021-06-24 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
WO2022150660A1 (en) * 2021-01-08 2022-07-14 10X Genomics, Inc. Antigen-binding polypeptides specific for coronaviruses and uses thereof
US20240400671A1 (en) * 2021-10-05 2024-12-05 Richard A. Shimkets Monoconal antibodies to il-25 and uses thereof
AU2023223413A1 (en) * 2022-02-24 2024-10-10 Sinomab Bioscience Limited Bispecific binding proteins against alarmins and uses thereof
EP4511634A4 (en) * 2022-04-18 2026-03-25 Access Medical Systems Ltd ENZYMATIC AMPLIFICATION HIGH SENSITIVITY BIOLAYER INTERFEROMETRY
JP2026513302A (ja) * 2023-03-31 2026-04-23 ノヴァロック バイオセラピューティクス, リミテッド 抗il-25抗体及びその使用方法
WO2026067830A1 (zh) * 2024-09-30 2026-04-02 深圳市小分子新药创新中心有限公司 抗il-25单域抗体及其衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトil−6受容体に対する高親和性抗体
GB0707505D0 (en) 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
GB0817891D0 (en) * 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
HUE036157T2 (hu) 2010-03-30 2018-06-28 Janssen Biotech Inc Humanizált IL-25 ellenanyagok
WO2012097126A2 (en) * 2011-01-13 2012-07-19 The University Of Maryland, Baltimore Il-25 treatment of obesity and metabolic disorders
JP2015521591A (ja) * 2012-06-12 2015-07-30 オレガ・バイオテック Il−17アイソフォームのアンタゴニストおよびその使用
US9840557B2 (en) 2014-09-23 2017-12-12 Regeneron Pharmaceuticals, Inc. Anti-IL-25 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2017533888A5 (enExample)
RU2650767C2 (ru) Интерлейкин-13-связывающие белки
KR101773505B1 (ko) 인간 il-13에 대한 결합 특이성을 갖는 항체 분자
JP2015514423A (ja) 抗baff−抗il−17二重特異性抗体
JP6876156B2 (ja) Il−17a及びil−17fに反応するモノクローナル抗体、及びその使用
CN102307899A (zh) 炎症、自身免疫疾病和心血管疾病的嗜酸细胞活化趋化因子-2(ccl24)抑制剂
JP2017528466A (ja) Cd40lに対するドメイン抗体を用いて自己免疫疾患を処置する方法
NZ730105B2 (en) Anti-il-25 antibodies and uses thereof
NZ730105A (en) Anti-il-25 antibodies and uses thereof
HK1256740B (en) Interleukin -13 binding proteins
HK1128495A (en) Interleukin -13 binding proteins
HK1128495B (en) Interleukin -13 binding proteins